A retrospective observational study of the natural history of advanced non–small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease-Reference-Cited by-同舟云学术

A retrospective observational study of the natural history of advanced non–small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease

Published:2021-09 Issue: Volume:159 Page:1-9
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Spira Alexander I.^ORCID,Tu Huakang,Aggarwal Shivani,Hsu Hil^ORCID,Carrigan Gillis^ORCID,Wang Xuena^ORCID,Ngarmchamnanrith Gataree,Chia Victoria,Gray Jhanelle E.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference52 articles.

1. About Lung Cancer;American Cancer Society,2020

2. Cancer statistics, 2020;Siegel;CA Cancer J. Clin.,2020

3. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment;Duma;Mayo Clin. Proc.,2019

4. Clinical Practice Guidelines in Oncology (NCCN Guidelines): Non-Small Cell Lung Cancer (Version 8.2020), National Comprehensive Cancer Network;National Comprehensive Cancer Network,2020

5. Osimertinib in resected EGFR-Mutated non-small-Cell lung Cancer;Wu;N. Engl. J. Med.,2020

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The histopathological spectrum and molecular changes associated with KRAS G12C mutation in non-small cell lung carcinoma;Pathology;2024-10

2. Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report;World Journal of Clinical Cases;2024-09-06

3. KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review;OncoTargets and Therapy;2024-08

4. Patient-reported outcomes in CodeBreak 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation;Lung Cancer;2024-08

5. Comparison Between Sotorasib with Docetaxel for the Treatment of Chinese Patients with Previously Treated NSCLC with KRASG12C Mutation: A Cost-Effectiveness Analysis to Inform Drug Pricing;Advances in Therapy;2024-06-18